Methods for regulating cancer
AssigneeThe Queen Elizabeth Hospital Research Foundation Inc.
InventorSally-Anne Stephenson
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for inhibiting cancerous growth of a cell using an antibody or an antigen-binding portion thereof which binds to an epitope of EphB4 polypeptide. Purified antibodies of EphB4 are also provided. The invention also provides methods for preventing or treating cancer. The invention also relates to methods of identifying agents that can inhibit cancerous growth of a cell.
Claims38
A method for inhibiting cancerous growth of a cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:
- 1).
A method for inhibiting cancerous growth of a cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO:
- 1), residues 201 to 245 of EphB4 (SEQ ID NO:
- 1), residues 220 to 244 of EphB4 (SEQ ID NO:
- 1) and residues 220 to 230 of EphB4 (SEQ ID NO:
- 1).
A method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:
- 1).
A method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO:
- 1), residues 201 to 245 of EphB4 (SEQ ID NO:
- 1), residues 220 to 244 of EphB4 (SEQ ID NO:
- 1) and residues 220 to 230 of EphB4 (SEQ ID NO:
- 1).
A method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:
- 1).
A method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO:
- 1), residues 201 to 245 of EphB4 (SEQ ID NO:
- 1), residues 220 to 244 of EphB4 (SEQ ID NO:
- 1) and residues 220 to 230 of EphB4 (SEQ ID NO:
- 1).
A method of identifying an agent which inhibits cancerous growth of a cell, the method comprising assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 200 to 400 of EphB4 (SEQ ID NO:1).
A method of identifying an agent which inhibits cancerous growth of a cell, the method comprising assessing the ability of the agent to bind to a polypeptide comprising a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO:
- 1), residues 201 to 245 of EphB4 (SEQ ID NO:
- 1) and residues 220 to 230 of EphB4 (SEQ ID NO:
- 1).
A purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 201 to 245 of EphB4 (SEQ ID NO:
- 1).
A purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 220 to 244 of EphB4 (SEQ ID NO:
- 1).
A purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 220 to 230 of EphB4 (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.